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When the South African (SA) antiretroviral therapy (ART) 
programme was rolled out in 2004, the treatment model for HIV-
positive Kaposi’s sarcoma (KS) patients shifted from symptomatic 
palliation to potential cure.[1] The advent of ART dramatically 
decreased KS incidence, morbidity and mortality in high-income 
countries.[2-4] SA addressed its large HIV epidemic by implementing a 
national ART programme,[5-7] but studies in the early ART era showed 
that KS morbidity and mortality were still high in SA, largely because 
ART coverage was still too low, and patients with KS were diagnosed 
late and many who needed chemotherapy did not receive it.[8]
While ART can bring about remission in early-stage KS, advanced 
KS requires systemic chemotherapy.[9] The Kaposi sarcoma AIDS 
Antiretroviral Therapy (KAART) trial in Durban showed 1-year 
overall survival rates of 77% in patients who received ART alone and 
those who received ART and chemotherapy (doxorubicin, bleomycin 
and vincristine), with no significant survival difference between the 
two treatment arms.[9] This and other studies suggest that in the 
context of ART and affordable standard-of-care cancer regimens, KS 
in HIV-positive patients can be treated effectively in resource-limited 
settings.[9,10]
Objective
The SA national ART programme grew rapidly after it was 
implemented in 2004. We sought to determine whether improved 
ART availability has begun to have a positive effect on the survival 
rate of HIV-positive KS patients in routine oncology care in the Steve 
Biko Academic Hospital (SBAH) medical oncology unit, a tertiary 
academic medical oncology unit in Pretoria, SA. We estimated 
survival rates in KS patients and changes over time, comparing the 
early (2004 - 2008) with the late (2009 - 2012) ART period.
Methods
Study design and setting
We retrospectively reviewed electronic and paper records of KS 
patients who accessed treatment at the SBAH medical oncology 
unit. Patients are referred to SBAH from northern Gauteng 
(Tshwane District, Mamelodi, Tembisa, Kalafong, Weskoppies and 
Bronkhorstspruit hospitals) and Mpumalanga (Witbank, Nelspruit, 
Philadelphia and Groblersdal hospitals) provinces. All HIV-positive 
KS patients were referred for ART and reviewed for eligibility for 
chemotherapy and/or radiation therapy after taking ART for at least 
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patient level. If ART coverage is extended, KS-associated morbidity and mortality are likely to drop.
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3 months. SBAH staff followed up patients who missed their visits by 
phone, and confirmed vital status (based on national identification 
number) with the SA Department of Home Affairs as part of routine 
care.
Participants
We included all adult patients (≥18 years) with clinically or 
histologically diagnosed KS who accessed oncology care at the SBAH 
medical oncology unit between May 2004 and September 2012. We 
excluded HIV-negative patients and those whose HIV status was 
unknown. Data on eligible KS patients were extracted from the SBAH 
medical oncology unit’s electronic database. We used a data collection 
form to capture additional information from paper records. We 
extracted the following data: demographic characteristics, baseline 
CD4+ count, HIV RNA viral load, haemoglobin concentration, 
other HIV-related comorbidities, date of KS diagnosis, KS site, AIDS 
Clinical Trials Group (ACTG) KS stage,[11,12] HIV status, ART use, 
date of starting ART, chemotherapy and radiation therapy, date 
of last visit, and patient outcome. Outcomes were defined as alive 
and in care at SBAH, referred/transferred to another facility, death, 
confirmed loss to follow-up (>6 months from missed scheduled 
visit, but confirmed to be alive through Home Affairs) and unknown 
outcome (>6 months from missed scheduled visit, but vital status 
unknown). Patients who were alive and in care at SBAH or referred/
transferred to another facility were classified as retained in care. Data 
were captured with EpiData software (EpiData version 3.1, EpiData 
Association, Denmark).
Data analysis
Patient characteristics by ART period were described with frequencies, 
medians and interquartile ranges (IQRs). Time was measured from 
date of KS diagnosis to date of death or last clinic visit. We used 
Kaplan-Meier survival functions to estimate overall survival and 
survival by ART period at 1 and 2 years’ follow-up. We also estimated 
survival and retention in care at 1 and 2 years’ follow-up. We used 
uni- and multivariable Cox regression models to determine changes 
over calendar years, defined as early (2004 - 2008) v. late (2009 - 2012) 
ART periods. In the multivariable Cox model, we adjusted the effect 
of ART period for gender, age, baseline CD4+ count, ACTG KS stage, 
history of tuberculosis (TB) infection, ART status at KS diagnosis, 
chemotherapy and radiation therapy. We performed multiple 
imputation, using chained equations to correct for missing ACTG 
KS stage (26.0% missing), baseline CD4+ count (11.5% missing) and 
baseline haemoglobin (8.1% missing) in the multivariable model. In 
sensitivity analyses, we fitted Cox regression models for the composite 
outcome of mortality and loss to follow-up. All analyses were done 
using Stata version 13 (Stata Corporation, USA).
Ethics approval
Informed consent was sought from all cancer patients in the SBAH 
medical oncology unit, requesting the use of their deidentified 
medical records for research publication. Ethics approval was granted 
by the University of Pretoria Faculty of Health Sciences Research 
Ethics Committee (ref. no. 199/2012).
Results
Characteristics of patients with AIDS-KS and  
changes over time
Between May 2004 and September 2012, a total of 374 KS patients 
received oncology care in the SBAH medical oncology unit. We 
excluded 13 HIV-negative patients (3.5%) and four patients of 
unknown HIV status (1.1%). We included all 357 HIV-positive patients 
(95.5%) in the analysis. Most (n=353, 98.9%) were black Africans, and 
62.7% were men. The median age was 38 (IQR 31 - 45) years for men 
and 34 (IQR 29 - 41) years for women (Table 1). The median baseline 
CD4+ count was 242 (IQR 130 - 403) cells/µL and the median baseline 
haemoglobin concentration 10.7 (IQR 9 - 12.5) g/dL. Of included 
patients, 25.2% (n=90) had a documented history of TB infection. 
Most patients had histologically confirmed KS (n=355, 99.4%). KS 
lesions were most commonly found on the lower limbs (n=281, 
78.7%) and 35.0% of patients (n=125) had oedema. About a quarter 
of the patients (n=93, 26.0%) were not staged. Of those with ACTG 
staging, 68.2% (180/264) had ACTG poor-risk stage. At the time of 
KS diagnosis, 64.1% (n=229) were on ART; another 103 started ART 
after KS diagnosis. Most patients received ART (n=332, 93.3%), nearly 
half (n=169, 47.3%) received chemotherapy, and 209 (58.5%) received 
radiation therapy. Of those who received ART, 66 (19.9%) received only 
ART, 67 (20.2%) received ART and chemotherapy, 97 (29.2%) received 
ART, chemotherapy and radiation, and 102 (30.7%) received ART and 
radiation therapy. Of the 169 patients who received chemotherapy, 145 
(85.8%) were treated with doxorubicin-bleomycin-vincristine (ABV) 
and 24 (14.2%) with oral etoposide (VP16).
The median follow-up time over the whole study period was 9.6 
(IQR 2.2 - 23) months.
Compared with the early ART period (2004 - 2008), patients 
diagnosed with KS in the late ART period (2009 - 2012) had, on 
average, higher CD4+ cell counts than those diagnosed in the early 
period (250 v. 233 cells/µL). Patients in the late ART period also 
had lower HIV RNA viral loads (median 3.2 v. 7.6 log10 copies/mL), 
and were more often on ART at KS diagnosis (72.7% v. 53.8%). In 
the later period, only 2.5% of patients received no ART before or 
after diagnosis; 12.1% had received no ART in the early period. The 
proportion of patients who received chemotherapy or radiotherapy 
did not change over time. Patients diagnosed in the late period 
were more likely to be male (66.7% v. 57.9%) and more likely to 
be diagnosed at advanced ACTG KS stages (56.6% v. 42.8%). The 
proportion of unstaged patients decreased from 31.4% in the early 
period to 21.7% in the late period.
Survival and retention in care
At end of the study period, 181 patients (50.7%) were alive and in 
care at SBAH, 95 (26.6%) had died, 39 (10.9%) were lost to follow-
up (>6 months from missed scheduled visit, but confirmed to be 
alive through Home Affairs), 23 (6.4%) had unknown outcomes 
(>6 months from missed scheduled visit, but vital status unknown), 
and 19 (5.3%) were discharged or transferred. Overall survival in 
all patients at 1 and 2 years’ follow-up was 78.5% (95% confidence 
interval (CI) 72.9 - 83.0) and 66.7% (95% CI 59.8 - 72.8), respectively. 
Patients diagnosed in the late ART period had higher survival rates 
than those diagnosed in the early ART period. One-year survival 
was 72.0% (95% CI 63.3 - 83.0) in the early period and 84.6% (95% 
CI  77.5 - 89.6) in the late period, while 2-year survival was 55.8% 
(95% CI 45.8 - 64.7) in the early period and 79.0% (95% CI 69.9 - 
85.6) in the late period (Table 2). Likewise, patients diagnosed in the 
late ART period had higher survival and retention rates than those 
diagnosed in the early ART period (Fig. 1). One-year survival and 
retention was 60.4% (95% CI 51.8 - 67.9) in the early period and 
72.3% (95% CI 64.3 - 78.8) in the late period, while 2-year survival 
and retention was 39.8% (95% CI 31.3 - 48.1) in the early period and 
66.7% (95% CI 57.6 - 74.2) in the late period (Table 2). Patients who 
received chemotherapy had higher survival and retention rates than 
those who did not. One-year survival and retention was 50.5% (95% 
CI 41.9 - 58.4) in the patients who did not receive chemotherapy and 
83.2% (95% CI 75.9 - 88.4) in the patients who did receive it, while 
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2-year survival and retention was 36.8% (95% CI 28.1 - 45.6) in the 
patients who did not receive chemotherapy and 66.9% (95% CI 57.5 - 
74.7) in those who did receive it.
Changes over time and predictors of mortality
In univariable analyses, patients in the late period were more likely to 
survive than those in the early period (hazard ratio (HR) 0.41, 95% 
CI 0.26 - 0.64) (Table 3). We confirmed this association (HR 0.37, 
95% CI 0.19 - 0.73) after adjusting for age, gender, baseline CD4+ 
count, baseline haemoglobin, ACTG KS stage, TB comorbidity, 
ART use at KS diagnosis, chemotherapy and radiation therapy. In 
both univariable and multivariable analyses, ACTG poor-risk stage 
(adjusted HR 2.88, 95% CI 1.36 - 6.09) was associated with increased 
mortality. A previous history of TB was associated with mortality in 
univariable (HR 1.64, 95% CI 1.05 - 2.57) but not in multivariable 
analyses. Receiving chemotherapy was associated with better survival 
in both univariable and multivariable analyses (adjusted HR 0.30, 
95% CI 0.15 - 0.61). After correction for missing data, radiation 
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Fig. 1. Survival and retention in oncology care by calendar period. (KS = 
Kaposi’s sarcoma.)
Table 1. Patient characteristics
Calendar period of KS diagnosis
Early ART period,  
2004 - 2008 (N=159)
Late ART period,  
2009 - 2012 (N=198) Total, 2004 - 2012 (N=357)
Demographic characteristics
Males, n (%) 92 (57.9) 132 (66.7) 224 (62.7)
Age at KS diagnosis (yr), median (IQR)
All patients 36 (30 - 45) 37 (31 - 42) 37 (30 - 43)
Males 38 (31 - 47) 37 (32 - 42) 38 (31 - 45)
Females 33 (30 - 42) 34 (28 - 41) 34 (29 - 41)
Black Africans, n (%) 156 (98.1) 197 (99.5) 353 (98.9)
Clinical characteristics
CD4+ count (cells/µL), median (IQR) 233 (136 - 396) 250 (124 - 409) 242 (130 - 403)
HIV viral load (log10 copies/mL) 7.6 (3.2 - 12.1) 3.2 (3.2 - 5.7) 3.2 (3.2 - 10.2)
Baseline haemoglobin (g/dL), median (IQR) 10.7 (9.1 - 12.4) 10.8 (8.9 - 12.6) 10.7 (9 - 12.5)
TB comorbidity, n (%) 37 (23.3) 53 (26.8) 90 (25.2)
Histological diagnosis, n (%) 158 (99.4) 197 (99.5) 355 (99.4)
Site of KS lesions, n (%)
Upper limbs 34 (21.4) 51 (25.8) 85 (23.8)
Lower limbs 119 (74.8) 162 (81.8) 281 (78.7)
Oral 42 (26.4) 37 (18.7) 79 (22.1)
Head 30 (18.9) 52 (26.3) 82 (23.0)
Trunk 35 (22.0) 42 (21.2) 77 (21.6)
Lymph nodes 9 (5.7) 7 (3.5) 16 (4.5)
Gastrointestinal 3 (1.9) 1 (0.5) 4 (1.1)
Lung* 34 (21.4) 23 (11.6) 57 (16)
Groin 11 (6.9) 33 (16.7) 44 (12.3)
Disseminated skin lesions 13 (8.2) 30 (15.1) 43 (12.0)
Presence of oedema 46 (28.9) 79 (39.9) 125 (35.0)
ACTG staging, n (%)
Good risk 41 (25.8) 43 (21.7) 84 (23.5)
Poor risk 68 (42.8) 112 (56.6) 180 (50.4)
Not staged 50 (31.4) 43 (21.7) 93 (26.0)
KS treatment, n (%)
On ART at KS diagnosis 85 (53.8) 144 (72.7) 229 (64.3)
Ever received ART 139 (87.9) 193 (97.5) 332 (93.3)
Received chemotherapy 72 (45.3) 97 (49.0) 169 (47.3)
Received radiation therapy 91 (57.2) 118 (59.6) 209 (58.5)
KS = Kaposi’s sarcoma; ART = antiretroviral therapy; IQR = interquartile range; TB = tuberculosis; ACTG = AIDS Clinical Trials Group; CT = computed tomography.
*Chest radiograph or CT scan suggestive of pulmonary KS.
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therapy (HR 0.52, 95% CI 0.33 - 0.81) was also associated with better 
survival in the multivariable analyses. HRs from the imputed model 
were similar to those from complete case analyses. In sensitivity 
analyses, predictors of the composite outcome of mortality and loss to 
follow-up were similar to predictors of mortality (Table 4).
Discussion
We found that survival of KS patients at the SBAH medical oncology 
unit has substantially improved in recent years. Mortality was 62.7% 
lower (adjusted HR 0.37, 95% CI 0.19 - 0.73) in the late (2009 - 2012) 
than in the early (2004 - 2008) ART period. This reduction was 
independent of patient (age, gender), disease progression (baseline 
CD4+ count, ACTG KS stage) or treatment (ART status at KS diag-
nosis, chemotherapy and radiotherapy) factors. Overall survival 
was 78.5% at 1-year follow-up and 66.7% at 2-year follow-up in 
KS patients receiving routine care in a tertiary hospital in Pretoria. 
The majority of patients continued to present with advanced KS at 
diagnosis.
We were the first to demonstrate that KS survival increased 
significantly after the advent of ART in an African setting. We 
found good survival rates of KS patients in routine care, treated with 
ART and chemotherapy (ABV or oral VP16) and/or radiotherapy 
for selected patients. The overall 1-year survival rate of 78.5% 
is comparable to survival estimates from other SA studies,[8,9,13] 
including a clinical trial that used similar chemotherapy regimens. [9] 
An observational study in the USA estimated 2-year survival rates 
Table 3. Predictors of mortality in patients diagnosed with KS
Univariable analysis,  
HR (95% CI)
Multivariable complete case 
analysis, HR (95% CI)
Multivariable imputed 
model, HR (95% CI)
Gender
Male 1 1 1
Female 0.92 (0.60 - 1.41) 0.85 (0.46 - 1.60) 0.71 (0.44 - 1.15)
Age 0.98 (0.95 - 0.99) 0.97 (0.94 - 1.01) 0.98 (0.95 - 1.00)
ART period
Early (2004 - 2008) 1 1 1
Late (2009 - 2012) 0.41 (0.26 - 0.64) 0.37 (0.19 - 0.73) 0.37 (0.23 - 0.60)
Baseline CD4+ count (cells/µL)
<100 1 1 1
100 - 199 0.82 (0.43 - 1.58) 0.77 (0.30 - 2.01) 0.80 (0.40 - 1.62)
200 - 349 0.80 (0.43 - 1.51) 1.17 (0.45 - 3.02) 1.14 (0.57 - 2.27)
350 - 500 0.63 (0.32 - 1.25) 1.09 (0.39 - 3.08) 1.22 (0.55 - 2.71)
>500 0.54 (0.24 - 1.21) 0.83 (0.27 - 2.56) 0.81 (0.35 - 1.89)
ACTG KS stage
Good risk 1 1 1
Poor risk 2.36 (1.25 - 4.43) 2.88 (1.36 - 6.09) 2.07 (1.13 - 3.77)
TB comorbidity
No TB 1 1 1
TB 1.64 (1.05 - 2.57) 1.29 (0.66 - 2.52) 1.45 (0.90 - 2.35)
ART use
Not on ART at KS diagnosis 1 1 1
On ART at KS diagnosis 0.79 (0.52 - 1.20) 0.82 (0.44 - 1.51) 0.96 (0.61 - 1.52)
Chemotherapy
No 1 1 1
Yes 0.30 (0.19 - 0.47) 0.30 (0.15 - 0.61) 0.28 (0.17 - 0.47)
Radiation therapy
No 1 1 1
Yes 0.57 (0.38 - 0.86) 0.72 (0.38 - 1.34) 0.52 (0.33 - 0.81
Haemoglobin 0.84 (0.77 - 0.92) 0.92 (0.80 - 1.05) 0.91 (0.83 - 1.01)
KS = Kaposi’s sarcoma; HR = hazard ratio; CI = confidence interval; ART = antiretroviral therapy; ACTG = AIDS Clinical Trials Group; TB = tuberculosis.
Table 2. Overall survival and retention in care at 1 and 2 years after KS diagnosis
Early ART era (2004 - 2008), % (95% CI) Late ART era (2009 - 2012), % (95% CI)
Overall survival
At 1 year 72.0 (63.3 - 83) 84.6 (77.5 - 89.6)
At 2 years 55.8 (45.8 - 64.7) 79.0 (69.9 - 85.6)
Overall survival and retention in care
At 1 year 60.4 (51.8 - 67.9) 72.3 (64.3 - 78.8)
At 2 years 39.8 (31.3 - 48.1) 66.7 (57.6 - 74.2)
KS = Kaposi’s sarcoma; ART = antiretroviral therapy; CI = confidence interval.
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comparable to what we found in the late ART period in SA (81% 
and 79%, respectively).[14] This suggests that ART in HIV-positive 
KS patients combined with standard-of-care chemotherapy regimens 
and/or radiotherapy in selected patients yields favourable survival 
outcomes and is a practical option in high-burden resource-limited 
settings. We confirmed the findings of other studies that advanced 
KS stage[10,11,15,16] predicts mortality, while chemotherapy[8,17] increases 
the chance of survival in KS patients. Unlike other SA studies,[13,18] we 
found no gender differences in mortality. Our study showed that both 
chemotherapy and radiation therapy were associated with improved 
survival. We suggest that referral for oncology care be considered for 
KS patients with failure of regression of lesions on ART alone, and 
for those with advanced disease. Recording of KS surveillance data 
at lower-level clinics will allow estimation of prognosis of KS across 
different stages.
Our findings reflect the success of the national ART programme, 
but also underline the need to reduce KS-associated morbidity and 
mortality further through early ART initiation. During the study 
period (2004 - 2012) the ART eligibility criteria were a CD4+ count 
<200/µL or a World Health Organization stage IV AIDS-defining 
condition.[19] Adult ART coverage rose from 5.1% in 2004 to 79% in 
2011,[6,7] and this improved ART coverage is reflected in the improved 
ART status of patients in the later ART period in our study. In spite 
of improved ART coverage, KS incidence in HIV-positive southern 
Africans remains unacceptably high, even in patients on ART,[20] 
because only patients with significant immune impairment were 
eligible for ART. This underscores the need and potential impact of 
the test-and-treat strategy that SA adopted from September 2016.[21]
Study strengths and limitations
Our study had several strengths and some weaknesses. The SBAH 
medical oncology unit has good paper and electronic record systems, 
traces defaulters by phone, and routinely confirms vital status with 
the SA Department of Home Affairs. This allowed us to ascertain 
deaths and document date of death, so that vital status was unknown 
in only 23 patients (6.4%). KS was pathologically confirmed in nearly 
all patients (n=355, 99.4%). Most KS patients had a documented 
HIV result (370/374), so we could include 95% of all KS patients 
in the analyses. The retrospective nature of our study did result in 
missing data, but we corrected for this with multiple imputation and 
confirmed the findings from the complete case analyses (Table 3). The 
KS patients in our study were mostly black Africans between 20 and 
50 years of age, which reflects national HIV prevalence distribution, 
where this key population has the highest HIV seroprevalence.[5,22] 
There was potential for selection bias in our study. We conducted our 
study at a tertiary academic hospital that may provide better care than 
most other healthcare facility levels. There was potential for selecting 
patients who had survived long enough to go through the referral 
Table 4. Predictors of mortality and loss to follow-up in patients diagnosed with KS
Univariable analysis,  
HR (95% CI)
Multivariable complete case 
analysis, HR (95% CI)
Multivariable imputed model, 
HR (95% CI)
Gender
Male 1 1 1
Female 0.98 (0.70 - 1.36) 0.70 (0.43 - 1.13 0.76 (0.53 - 1.10)
Age 0.99 (0.97 - 1.00) 0.99 (0.96 - 1.01) 0.98 (0.96 - 1.00)
ART period
Early (2004 - 2008) 1 1 1
Late (2009 - 2012) 0.45 (0.32 - 0.64) 0.39 (0.24 - 0.64) 0.40 (0.28 - 0.58)
Baseline CD4+ count (cells/µL)
<100 1 1 1
100 - 199 0.78 (0.47 - 1.30) 0.70 (0.34 - 1.42) 0.74 (0.42 - 1.30)
200 - 349 0.81 (0.50 - 1.32) 1.02 (0.50 - 2.09) 0.93 (0.53 - 1.63)
350 - 500 0.62 (0.36 - 1.06) 0.97 (0.45 - 2.10) 1.09 (0.57 - 2.08)
>500 0.51 (0.27 - 0.97) 0.73 (0.31 - 1.72) 0.78 (0.39 - 1.54)
ACTG KS stage
Good risk 1 1 1
Poor risk 2.37 (1.46 - 3.83) 2.71 (1.53 - 4.79) 1.89 (1.19 - 3.03)
TB comorbidity
No TB 1 1 1
TB 1.46 (1.02 – 2.09) 1.26 (0.75 – 2.11) 1.22 (0.83 – 1.81)
ART use
Not on ART at KS diagnosis 1 1 1
On ART at KS diagnosis 0.96 (0.69 - 1.34) 1.09 (0.68 - 1.75) 1.20 (0.84 - 1.72)
Chemotherapy
No 1 1 1
Yes 0.33 (0.24 - 0.47) 0.39 (0.23 - 0.67) 0.35 (0.23 - 0.52)
Radiation therapy
No 1 1 1
Yes 0.64 (0.47 - 0.89) 0.91 (0.57 - 1.46) 0.64 (0.46 - 0.90)
Haemoglobin 0.86 (0.80 - 0.92) 0.92 (0.83 - 1.02) 0.93 (0.86 - 1.01)
KS = Kaposi’s sarcoma; HR = hazard ratio; CI = confidence interval; ART = antiretroviral therapy; ACTG = AIDS Clinical Trials Group; TB = tuberculosis.
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system, those who had better healthcare access and also those who 
were sick enough to warrant referral to a tertiary hospital.[23] We had 
a total of 374 KS patients over the 8-year study period, which is a very 
small number given the high incidence of KS in HIV-positive people 
in SA. It is likely that many patients with early-stage KS were never 
referred for oncology care and were treated with ART only at their 
local HIV clinics. Furthermore, SA is a middle-income country and 
access to cancer care may be better than in other African settings,[24] 
making these findings less generalisable to other African settings.
Conclusions
Large national ART programmes like the one in SA can successfully 
reduce KS-related mortality at the individual patient level. If ART 
coverage is extended, KS-associated morbidity and mortality are 
likely to drop.
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